

1 **Title**

2 Histology of type 3 macular neovascularization and microvascular anomalies in treated
3 age-related macular degeneration: a case study

4 **Authors**

5 Andreas Berlin MD MS,^{1,2} Diogo Cabral MD,^{3,4} Ling Chen, MD PhD,^{1,5} Jeffrey D
6 Messinger DC,¹ Chandrakumar Balaratnasingam MD PhD,⁶⁻⁸ Randev Mendis MD,⁹
7 Daniela Ferrara MD PhD,¹⁰ K. Bailey Freund MD,^{3,11} Christine A Curcio PhD^{1*}

8

9 ¹ Department of Ophthalmology and Visual Sciences, School of Medicine, University of
10 Alabama at Birmingham, Birmingham AL, USA; ² Department of Ophthalmology,
11 University Hospital Würzburg, Würzburg, Germany; ³ Vitreous Retina Macula
12 Consultants of New York NY, USA; ⁴ NOVA Medical School Research, Universidade
13 NOVA de Lisboa, Portugal; ⁵ The First Affiliated Hospital of Chongqing Medical
14 University, Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute,
15 Chongqing, China; ⁶ Centre for Ophthalmology and Visual Science, University of
16 Western Australia, Perth, Australia; ⁷ Lions Eye Institute, Nedlands, Western Australia,
17 Australia; ⁸ Department of Ophthalmology, Sir Charles Gairdner Hospital, Western
18 Australia, Australia; ⁹ Canberra Retina Center, Canberra Australia, ¹⁰ Genentech, South
19 San Francisco, CA, USA; ¹¹ Department of Ophthalmology, New York University
20 Grossman School of Medicine, New York NY, USA

21

22 *Corresponding author

23

24 **Short title** Intraretinal vascular morphologies in treated AMD

25 **Word count** 4117

26 **Figures** 11

27 **Tables** 2

28 **Supplementary** 5 figures, 1 video, 2 tables

29 **Corresponding Address**

30 Christine A. Curcio, PhD; Department of Ophthalmology and Visual Sciences; EyeSight

31 Foundation of Alabama Vision Research Laboratories; 1670 University Boulevard Room

32 360; University of Alabama at Birmingham, School of Medicine; Birmingham AL 35294-

33 0099; Email: christinecurcio@uabmc.edu

34 **Key words**

35 age-related macular degeneration, type 3 macular neovascularization, deep retinal age-

36 related microvascular anomalies, vascular morphology, optical coherence tomography

37 angiography, histopathology, electron microscopy.

38

39

Intraretinal vascular morphologies in treated AMD

40 **Abstract**

41 **Objective/Purpose**

42 To investigate intraretinal neovascularization and microvascular anomalies by correlating
43 in vivo multimodal imaging with corresponding ex vivo histology in a single patient.

44 **Design**

45 A case study comprising clinical imaging from a community-based practice, and
46 histologic analysis at a university-based research laboratory (clinicopathologic
47 correlation).

48 **Participants**

49 A white woman in her 90's treated with numerous intravitreal anti-vascular endothelial
50 growth factor (VEGF) injections for bilateral type 3 macular neovascularization (MNV)
51 secondary to age-related macular degeneration (AMD).

52 **Intervention(s)/ Methods**

53 Clinical imaging comprised serial infrared reflectance, eye-tracked spectral-domain
54 optical coherence tomography (OCT), OCT angiography, and fluorescein angiography.
55 Eye tracking, applied to the two preserved donor eyes, enabled correlation of clinical
56 imaging signatures with high-resolution histology and transmission electron microscopy.

57 **Main Outcome(s) and Measure(s)**

58 Histologic/ ultrastructural descriptions and diameters of vessels seen in clinical imaging.

59 **Results**

60 Six vascular lesions were histologically confirmed (type 3 MNV, n=3; deep retinal age-
61 related microvascular anomalies (DRAMA), n=3). Pyramidal (n=2) or tangled (n=1)
62 morphologies of type 3 MNV originated at the deep capillary plexus (DCP) and extended
63 posteriorly to approach without penetrating persistent basal laminar deposit. They did
64 not enter the sub-RPE-BL space or cross Bruch's membrane. Choroidal contributions
65 were not found. The neovascular complexes included pericytes and non-fenestrated

Intraretinal vascular morphologies in treated AMD

66 endothelial cells, within a collagenous sheath covered by dysmorphic retinal pigment
67 epithelial cells. DRAMA lesions extended posteriorly from the DCP into the Henle fiber
68 and the outer nuclear layers, without evidence of atrophy, exudation, or anti-VEGF
69 responsiveness. Two DRAMA lacked collagenous sheaths. External and internal
70 diameters of type 3 MNV and DRAMA vessels were larger than comparison vessels in
71 the index eyes or aged normal and intermediate AMD eyes.

72 **Conclusions**

73 Type 3 MNV vessels reflect specializations of source capillaries and persist during anti-
74 VEGF therapy. The collagenous sheath of type 3 MNV lesions may provide structural
75 stabilization. If so, vascular characteristics may be useful in disease monitoring in
76 addition to fluid and flow signal detection. Further investigation with longitudinal imaging
77 before exudation onset will help determine if DRAMA are part of the type 3 MNV
78 progression sequence.

79

80

81 **Abbreviations**

82 AMD, age-related macular degeneration; BLamD, basal laminar deposit; BrM, Bruch's
83 membrane; ChC, choriocapillaris; Ch, choroid; DCP, deep capillary plexus; DRAMA,
84 deep retinal age-related microvascular anomalies; ELM, external limiting membrane;
85 ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluorescein angiography; GCL,
86 ganglion cell layer; HFL, Henle fiber layer; INL, inner nuclear layer; IPL, inner plexiform
87 layer; IS, inner segment; MNV, macular neovascularization; nvAMD, neovascular age-
88 related macular degeneration; OCT, optical coherence tomography; OCTA, optical
89 coherence tomography angiography; ONL, outer nuclear layer; OPL, outer plexiform
90 layer; OS, outer segment; RPE, retinal pigment epithelium.

91

Intraretinal vascular morphologies in treated AMD

92 **Introduction**

93 Type 3 macular neovascularization (type 3 MNV) is a subtype of neovascular age-
94 related macular degeneration (AMD).¹ Unlike type 1 MNV, which arises from the choroid,
95 type 3 MNV originates in the neurosensory retina.^{2, 3} Female gender, older age, and
96 presence of subretinal drusenoid deposits confer risk for type 3 MNV.^{4, 5} Type 3 MNV is
97 diagnosed in a third of Caucasian patients presenting with unilateral neovascular AMD⁶
98 and may be underestimated overall. Fellow eyes often convert to neovascular AMD
99 within 3 years.⁷⁻⁹ Early lesions respond well to intravitreal anti-vascular endothelial
100 growth factor (VEGF) therapy, unlike chronic lesions.^{2, 10} New information about type 3
101 MNV and related vascular anomalies from histopathology, as provided herein, could
102 support improved detection and treatment decisions in affected patients.

103 Recent clinical imaging studies have elucidated type 3 MNV pathophysiology.
104 Three stages are defined based on structural optical coherence tomography (OCT).
105 Precursors to Stage 1 are hyperreflective foci (HRF) at the level of the deep capillary
106 plexus (DCP), often near drusen. Stage 1 includes an intraretinal hyperreflective lesion
107 and cystoid macular edema. In Stage 2, outer retinal disruption appears. At Stage 3, the
108 hyperreflective lesion extends into the sub-RPE basal lamina (BL) space, associated
109 with a pigment epithelium detachment.² By color fundus photography, fluorescein
110 angiography (FA), and OCT, type 3 MNV exhibit a specific regional distribution and
111 pattern of hemorrhage.¹¹⁻¹³ Lesions localize preferentially to the inner ring of the Early
112 Treatment of Diabetic Retinopathy Study (ETDRS) grid. Flame-shaped intraretinal
113 hemorrhages are located over type 3 MNV lesions, pointing toward the fovea. OCT
114 angiography (OCTA) with 3-dimensional reconstruction and display shows vertically
115 oriented components of type 3 MNV. Using this technology, Borelli et al describe two
116 morphologic phenotypes ('filiform' and 'saccular') of advanced type 3 MNV.¹⁴

Intraretinal vascular morphologies in treated AMD

117 Prior clinicopathological correlation has elucidated some of the cellular detail
118 corresponding to the OCT-based stages.^{15, 16} Neovascular complexes originating at the
119 DCP have a vertical and downward trajectory. These complexes expand posteriorly and
120 cross persistent basal laminar deposit (BLamD) to enter the sub-RPE-BL space. Some
121 complexes appear like base-down pyramids that are ensheathed by collagenous
122 material.^{3, 16} Participatory cells include macrophages, VEGF-positive fibroblasts,
123 lymphocytes, Müller cell processes, and subducted RPE cells.^{15, 16} Hence, ischemia and
124 inflammation may promote the development and progression of type 3 MNV.^{15, 16}

125 Microvascular abnormalities involving the DCP include microaneurysms,
126 telangiectasia, perifoveal exudative anomalous vascular complex (PEVAC), and capillary
127 macroaneurysms.¹⁷⁻²² PEVAC was initially described in non-AMD eyes as an isolated
128 aneurysmal dilation of a retinal capillary originating between the superficial and deep
129 plexuses, with exudation that is unresponsive to anti-VEGF.^{17, 22, 23} Deep retinal age-
130 related microvascular anomalies (DRAMA) are recently proposed as DCP alterations in
131 the setting of AMD findings like soft drusen and intraretinal HRF. Eyes with DRAMA
132 show abnormal horizontal or vertical vessels with a diameter of >50 μm and/or a location
133 below the posterior border of the outer plexiform layer (OPL).²⁴ In contrast to type 1
134 MNV,²⁵ precursors, early stages, and potential masqueraders for type 3 MNV, which
135 may include DRAMA, are not described at the histologic level.²⁶ Human eyes with
136 longitudinal clinical imaging are especially valuable sources for such information.³

137 Herein we directly compared longitudinal OCT and angiographic signatures of
138 intraretinal neovascularization and microvascular anomalies to corresponding histology.
139 We analyzed both eyes of a single patient who had received intravitreal anti-VEGF
140 treatments for type 3 MNV over the course of 5 years (right eye) and 9 months (left eye).

141

142

Intraretinal vascular morphologies in treated AMD

143 **Methods**

144 Compliance

145 Approval for this study was obtained by Institutional review at the University of
146 Alabama at Birmingham (protocol #300004907). The study was conducted in
147 accordance with the tenets of the Declaration of Helsinki and the Health Insurance
148 Portability and Accountability Act of 1996.^{27, 28}

149 Clinical course

150 A white, pseudophakic woman in her 90's received comprehensive ophthalmologic
151 examination and multimodal imaging during a 5-year follow-up for bilateral type 3 MNV
152 secondary to AMD. The patient presented 5 years prior to death with exudative type 3
153 MNV in the right eye. Over 5 years, she received a total of 37 intravitreal anti-VEGF
154 injections over approximately 6 fluid resorption cycles in the right eye (12 x 0.5 mg/ 0.05
155 ml ranibizumab then 25 x 2 mg/ 0.05 ml aflibercept). One fluid resorption cycle is defined
156 as the time in weeks and the number of injections needed from initial detection of
157 intraretinal/ subretinal edema on OCT until complete absence of edema on OCT. The
158 left eye was diagnosed with exudative type 3 MNV 4 years after the right eye. Over 9
159 months, the left eye received a total of 6 intravitreal anti-VEGF injections over
160 approximately 2 fluid resorption cycles (12 x 0.5 mg/ 0.05 ml ranibizumab). Her general
161 medical history included dyslipidemia and paroxysmal atrial fibrillation. Six months
162 before death, the patient was diagnosed with gallbladder adenocarcinoma. Her last anti-
163 VEGF treatment before death due to adenocarcinoma was 3 and 2 months for the left
164 and right eye, respectively.

165 Clinical image capture and analysis

166 All images were acquired using Spectralis HRA+OCT (Heidelberg Engineering,
167 Heidelberg, Germany). Available for review were 11 (right eye) and 7 (left eye) eye-

Intraretinal vascular morphologies in treated AMD

168 tracked spectral domain OCT volumes (6 mm x 6 mm horizontal and radial scans; 20° x
169 20° field). FA was available for both eyes at first presentation and 4 years later.

170 One eye-tracked spectral domain OCTA volume (3 mm x 3 mm horizontal scans,
171 256 B-scans at 6 µm spacing, 10° x 10° field, ART 5, quality 34 dB) was obtained of the
172 right eye 3.5 years after presentation.²⁹ An investigational version of Heidelberg Eye
173 Explorer (v. 6.16.100.701, Heidelberg Engineering, Heidelberg, Germany) was used for
174 analysis, processing, and post-processing of data.^{3,30} Projection artifact was removed via
175 3-dimensional vessel-shape estimation and a Gaussian blur filter.^{3,30} Raw (floating point)
176 data were exported as a .VOL file. Linear quadratic estimation (noise variance estimate
177 of 0.05 and a gain of 0.8) was applied using a code designed in MATLAB version
178 R2019b (Natick, Massachusetts: The MathWorks Inc.; 2019) to visualize neovascular
179 lesions at different angles of rotation, volume rendering and analysis of processed OCTA
180 data utilized Imaris v9.5 (Bitplane, Andor Technology plc.).³¹ The Filament Tracer tool
181 was used to trace superficial arteries and veins after evaluation of dye circulation in FA.
182 Video recording and still annotations were annotated to highlight specific details from
183 structural and flow data.

184 Previous reports indicated both eccentricity- and hemifield-dependent
185 asymmetries in the spatial distribution of type 3 MNV.^{11, 12, 32} Thus, for potential
186 mechanistic insight for tissue-level associations, location of vascular lesions was
187 documented. Lesion distance from the fovea was calculated using the OCT volume and
188 NIR en face image using a custom ImageJ plug-in 'Spectralis Browser OCT', available at
189 <https://sites.imagej.net/CreativeComputation/>. Meridional position was documented
190 using the sectors of the ETDRS grid.^{33,34}

191

Intraretinal vascular morphologies in treated AMD

192 Histology preparation and image analysis

193 As described,³⁵ globes were recovered 2:05 hours after death and preserved in
194 buffered 1% paraformaldehyde and 2.5% glutaraldehyde. Pre-mortem eye-tracked OCT
195 volumes were registered to post-mortem OCT volumes of the same globes.³⁶ A
196 rectangular tissue block containing fovea and optic nerve was post-fixed in 1% osmium –
197 tannic acid – paraphenylenediamine and embedded in epoxy resin. A tissue block 8 mm
198 x12 mm wide was processed for stepped sections at 30-60 μm intervals. Interleaved 30
199 μm -thick slabs were re-embedded for transmission electron microscopy (TEM). Sub-
200 micrometer sections stained with toluidine blue were scanned using a 60X oil immersion
201 objective.³⁷ Tissue sections on 112 (right eye) and 87 (left eye) glass slides spanning a
202 distance of 5453 μm (right eye) and 4243 μm (left eye) centered on the two foveas were
203 matched to clinical OCT scans by comparing overall tissue contours.

204 DRAMA vessels are defined by a diameter criterion ($>50 \mu\text{m}$),²⁴ and our previous
205 and current observations indicated that a collagenous sheath surrounds type 3 MNV
206 neovessels. Further, OCTA shows only the moving blood cell column and not the
207 collagenous sheath. Therefore, we manually measured internal (luminal) and external
208 cross-sectional diameters of vessels ('oval' tool, FIJI Is Just; ImageJ 2.0.0-rc- 69/1.52p;
209 www.fiji.sc); Type 3 MNV vessels meandered over several glass slides, and sections on
210 each slide were measured. To contextualize neovessel measurements, DCP vessels on
211 either side of the area directly involved in exudation in the index case were also
212 measured. Further, vessels aligned along the outer border of the INL of intermediate
213 AMD eyes and age-similar controls (n= 8 each) on the Project MACULA website of AMD
214 histopathology were also measured.²⁵ Because vessels could run longitudinally within a
215 section, we report a minimal cross-section diameter (approximated by Feret diameter in
216 ImageJ for ellipses). Due to small numbers, these data were not analyzed statistically.

217

Intraretinal vascular morphologies in treated AMD

218 **Results**

219 **Table S1** lists all figures to provide an overview of all imaging data pieces.

220 Classification of lesions and longitudinal clinical imaging

221 We first classify vascular complexes in the two eyes at one time point then
222 describe them in longitudinal clinical imaging and detailed histology. **Table 2** lists
223 hyperfluorescent lesions seen by FA 11 months before death (**Figure 1**). Six of 7 lesions
224 localized to the inner ring of the ETDRS grid (0.5-1.5 mm eccentricity), with the seventh
225 at 1.52 mm. There was no predilection for any one sector. Six of 7 lesions were
226 confirmed as vascular by histology, and the seventh (**Figure S2**) could not be found.
227 Lesion morphology was categorized as tangled type 3 MNV (n=1), pyramidal type 3
228 MNV (n=2), or DRAMA (n=3). As seen previously,^{3, 16} pyramidal type 3 MNV was
229 defined as a focal, vertically extending neovessel complex. Tangled type 3 MNV was
230 defined as a horizontally extending neovessel complex. DRAMA was defined as
231 anomalous vascular elements extending posterior to the DCP and into the HFL/ONL, i.e.,
232 anterior to the ELM.²⁴ Hyperfluorescent lesions in the right eye due to window defects
233 were reported elsewhere.³⁸

234 At initial presentation 5 years before death, the right eye exhibited multiple
235 instances of MNV secondary to AMD with multifocal leakage on FA (**Figure S3**). At this
236 time, fluid was not detected in the left eye (**Figure S4**). Four years later and 11 months
237 before death (**Figure 1**), the left eye was diagnosed with exudative type 3 MNV due to
238 AMD. By this time, the right eye had received 32 intravitreal anti-VEGF injections at
239 intervals of 4-8 weeks resulting in 4 fluid resorption cycles.

240 Pyramidal (OD 2, OS 4) and tangled (OD 1) type 3 MNV

241 Pyramidal type 3 MNV (OS 4) closely resembles previously described OD 2⁴ in
242 terms of location, OCT appearance, and histologic features (**Figure 1, Figure 5, Figure**
243 **6**, respectively). In brief, OS 4 is a vertically oriented, pyramidal-shaped, intraretinal

Intraretinal vascular morphologies in treated AMD

244 lesion located in the nasal sector of the ETDRS inner ring, with heterogeneous
245 hyperreflectivity on OCT (**Figure 5**). On histology, this lesion corresponds to a collagen-
246 ensheathed neovascular complex that extends from the OPL/INL border through the
247 HFL /ONL (**Figure 6A**). The complex is flanked by RPE cells that extend off the top of
248 the pyramid and along a DCP vessel (**Figure 6B**). The pyramid base adheres to
249 denuded and persistent BLamD, which drapes a calcified druse (**Figure 6A&B**).⁴ The
250 vessel did not enter the subRPE-BL space, and no choroidal contribution was found.

251 Transmission electron microscopy of this pyramidal lesion reveals endothelial
252 cells and pericytes (**Figure 7A**). Endothelial cells are not fenestrated (**Figure 7B**), like
253 endothelial cells of the DCP and unlike endothelial cells of the choriocapillaris (**Figure**
254 **7C&D**). Other vessel wall components, e.g., smooth muscle cells, connective tissue, or a
255 3-layer arterial configuration, cannot be identified. In RPE cells arrayed along the sloping
256 sides of the calcified druse, lipofuscin becomes less electron-dense, smaller, and less
257 tightly packed (**Figure 7E**), in a smooth transition. These findings suggest
258 transdifferentiation, rather than ingestion of RPE organelles by invading phagocytes.

259 Next we consider tangled type 3 MNV (OD 1), for which en face OCTA (**Figure**
260 **8A2**) and OCT with flow overlay (**Figure 8A3**) shows persistent flow signal. Over time,
261 the extent of intraretinal fluid surrounding OD 1 in the INL and HFL fluctuates (**Figure**
262 **8B2, Figure 8C2**, respectively). Volume rendering of structural OCT and OCTA together
263 highlights flow within a hyperreflective lesion at the ONL and bacillary layer (**Figure 9A,**
264 **Video S1**). Inflow and outflow vessels can be connected to a superficial artery and vein,
265 respectively (**Figure 9B&C**). The RPE/BrM complex below the lesion is split by
266 hyporefective material producing a double layer sign (**Figure 7B2**).³⁹ Numerous HRF
267 are present in the INL (**Figure 8C2**).

268 Histologic analysis reveals components of tangled type 3 MNV (OD 1, **Figure**
269 **8D**). Magnified histology shows a vascular complex spanning 249 μm horizontally,

Intraretinal vascular morphologies in treated AMD

270 extending into the superior perifovea (**Figure S10**). The complex is partly ensheathed by
271 collagenous material and flanked by intraretinal RPE cells. The INL/OPL border
272 subsides where the vascular lesion extends through the HFL/ONL (**Figure S10C**). The
273 ELM subsides at both edges of the calcified druse (yellow arrows in **Figure S10B**).
274 Bruch's membrane appears intact without evidence of a choroidal contribution to the
275 MNV lesions, or evidence of MNV contributing to the OCT double layer sign (**Figure**
276 **S10A-C**). Neovessels within the INL are moderately dilated, suggesting drainage
277 venules (**Figure S10A**).⁴⁰

278 To summarize, vascular geometry and thickness of the collagenous sheath
279 differentiates tangled versus pyramidal type 3 MNV. The sheath surrounding the tangled
280 complex is thin (**Figure S10**), and that surrounding pyramidal type 3 MNV is thick
281 (**Figure 6**). Otherwise, the two subtypes are comparable.

282 DRAMA, in the setting of anti-VEGF therapy

283 As shown below, all three instances of DRAMA (OS 1, OS 3, and OD 3) exhibit
284 mild hyperfluorescence on venous and recirculation phase FA 11 months before death.
285 In histology, all three localize above a horizontal ELM, signifying lack of atrophy.

286 OS 1 includes a vessel extending from the INL into the ONL (**Figure 11A**). Like
287 type 3 MNV lesions, this DRAMA lesion is located above a soft druse with BLamD and
288 altered RPE at its apex (**Figure 11C**). Unlike type 3 MNV, OS 1 does not have a
289 collagenous sheath, and the OPL does not subside (**Figure 11C2**).

290 Corresponding to FA, OCT of OS 3 shows an intraretinal hyperreflective,
291 stacked lesion, without intraretinal cysts (**Figure 12A**). Over time, a plume of HRF
292 extends nasally, still without evidence of cysts (**Figure 12C**).^{41, 42} In histology, an RPE
293 tower atop a soft druse extends into the OPL (**Figure 12D**). This RPE complex
294 surrounds like a gripping hand a vessel extending downward from the DCP (**Figure**
295 **13A&B**). By light microscopy, the extending vessel in OS 3 resembles DRAMA OS 1

Intraretinal vascular morphologies in treated AMD

296 (Figure 11) in its location above a soft druse with thick BLamD and a thinned RPE layer.
297 By transmission electron microscopy, OS 3 (Figure S14) resembles type 3 MNV lesions
298 but lacks a collagenous sheath. Endothelial cells in OS 3 lack fenestrations (Figure 13C),
299 like endothelial cells of the DCP and unlike endothelial cells of the choriocapillaris
300 (Figure 13D&E) Other vessel wall components cannot be identified. The RPE complex
301 is multicellular, with some multinucleated cells (Figure S14). Organelle packing and
302 electron density is similar to in-layer RPE cells (not shown).

303 OCTA flow overlay of DRAMA OD 3 shows an intraretinal hyperreflective lesion
304 containing a pair of vascular outpouchings (Figure 15C). Corresponding histology
305 displays a pair of deeply descending vessels without significant intraretinal fluid (Figure
306 15D). Like type 3 MNV, the vessel complex of this DRAMA is ensheathed by a thin layer
307 of collagenous material and dives from the INL into the HFL (Figure 16A). Unlike type 3
308 MNV, the vessels do not extend past the HFL, and there is no subsidence of the ELM.
309 RPE organelles appear near the vessel complex (Figure 16B).

310 Vessel diameters of vascular lesions and comparison vessels

311 Table S3 shows internal and external vessel diameters of type 3 MNV and
312 DRAMA, as well as DCP vessels in the index case and donor eyes (8 intermediate AMD,
313 83.4 ± 11.6 years; 8 controls, 84.1 ± 6.7 years). Five of the 6 index case lesions are
314 noticeably larger (2.5-3-fold) than the comparison vessels. External vessel diameters of
315 type 3 MNV (OD 1, OD 2, OS 4 $15.02 \mu\text{m} \pm 3.81 \mu\text{m}$; $21.35 \mu\text{m} \pm 10.79 \mu\text{m}$; $12.46 \mu\text{m} \pm$
316 $0.95 \mu\text{m}$, respectively) are larger than nearby DCP diameters ($7.18 \mu\text{m} \pm 1.11 \mu\text{m}$). They
317 are also larger than vessel diameters in intermediate AMD ($6.79 \mu\text{m} \pm 1.05 \mu\text{m}$) and
318 controls ($7.86 \mu\text{m} \pm 1.47 \mu\text{m}$, Table S3A). In DRAMA, external vessel diameters of OS 1
319 and OS 3 ($13.39 \mu\text{m} \pm 2.68 \mu\text{m}$; $17.97 \mu\text{m} \pm 1.08 \mu\text{m}$) are considerably larger than the
320 comparison vessels. A similar pattern is seen for internal vessel diameters (Table S3B).

Intraretinal vascular morphologies in treated AMD

321 An overview of unifying and distinguishing features of type 3 MNV and DRAMA,

322 combining this and prior reports, is provided in **Table 4**.^{3, 16, 24}

323

324

Intraretinal vascular morphologies in treated AMD

325 Discussion

326 In two anti-VEGF treated eyes of a single patient with multifocal intraretinal
327 neovascular AMD, we compare longitudinal multimodal clinical imaging and histology of
328 type 3 MNV and DRAMA (Table 2, Table 4). Although one patient, clinical and imaging
329 characteristics are typical of multifocal type 3 MNV, which is frequently bilateral (55%).⁴³
330 Moreover, the presence of multifocal intraretinal lesions without any type 1 MNV
331 highlights the clinical and pathophysiologic differences between types 3 and 1 MNV.^{11-13,}
332 ^{43, 44} Type 3 MNV is distinguished by intraretinal origin,^{1, 2, 45} high frequency of near-term
333 bilateral involvement,⁷⁻⁹ and significant choroidal thinning with reduced perfusion.^{46, 47}
334 Patients with type 3 MNV are older at initial diagnosis than patients with choroidal-
335 originating MNV, and mostly do not have such vascular lesions themselves.^{11, 12, 44}

336 In our case, treated type 3 MNV has two morphologic phenotypes, pyramidal (OD
337 2, OS 4) or tangled (OD 1). All three analyzed complexes originate at the DCP and
338 extend posteriorly to approach persistent BLamD but do not enter the sub-RPE-BL
339 space or cross BrM. These two phenotypes may correspond to those seen by Borelli et
340 al in treatment-naïve type 3 MNV eyes with rotational three-dimensional OCTA. These
341 authors describe 26 lesions as ‘filiform’ and 9 lesions as ‘saccular’, which appear similar
342 in shape to pyramidal (filiform) and tangled (saccular).¹⁴ Similarly, in our patient, we find
343 more pyramidal lesions than tangled. It remains to be determined if saccular and filiform
344 lesions differ in spatial distribution and time of onset.¹⁴

345 Our previous description of pyramidal Type 3 MNV included endothelial cells in a
346 thick collagenous matrix and dysmorphic RPE cells scattered along the neovascular
347 stalk.¹⁶ The two instances in this case (OD2 and OS4)³ add pericytes plus a nearly
348 continuous covering by highly pigmented RPE (OS4). These data support the early
349 involvement of migratory RPE in type 3 MNV.^{2, 48} The presence of the sheath
350 distinguishes lesions from unaffected DCP vessels. The main differences between

Intraretinal vascular morphologies in treated AMD

351 pyramidal and tangled lesions are the larger horizontal extent and thinner collagenous
352 sheath of tangled.³ Endothelial cells of tangled vessels, and presumably also those in
353 pyramidal, lack fenestrations like the source vessels in the DCP.

354 As before,¹⁶ we did not see vessels of choroidal origin in the sub-RPE space, as
355 reported for advanced type 3 MNV in histopathology and clinic patients.^{14, 43, 49-51} Nor did
356 we see DCP-originating vessels penetrate through BLamD and enter the sub-RPE- BL
357 space. This level of activation is suggested as necessary for exudation, based on OCTA
358 imaging without projection artifact removal to reduce spurious signal directly under type
359 3 MNV.⁵² Using volumetric artifact removal, we did not see OCTA flow signal in the sub-
360 RPE-BL space (**Figure 8**). It is possible that anti-VEGF treatment rendered invisible
361 downward projections from the DCP or upward projections from the choriocapillaris. We
362 think this is unlikely, because neo-capillaries may shrink after treatment, but they do not
363 disappear.^{53, 54} Our use of stepped epoxy-resin sections for high-resolution microscopy
364 over large areas may miss key details. Nevertheless, in all analyzed sections of this
365 case, both BLamD and Bruch's membrane were intact. Longitudinal imaging before
366 exudation onset would be helpful in understanding this phase of type 3 MNV
367 progression.

368 The thick collagenous sheath of pyramidal type 3 MNV lesions may have
369 implications for clinical monitoring, as follows. All type 3 MNV lesions responded to anti-
370 VEGF with temporary resolution of exudation and persistence over several fluid
371 absorption cycles. By OCTA, some early-stage type 3 MNV lesions appear to completely
372 regress while treatment of later-stage type 3 MNV require continuing therapy.^{2, 51} Further,
373 type 3 MNV can recur after becoming undetectable on OCTA during treatment.^{52, 55}
374 Lesions with thick sheaths remain detectable by structural OCT long after treatment.⁵⁴
375 While the role of basement membranes is well established for vascular endothelial

Intraretinal vascular morphologies in treated AMD

376 cells,⁵⁶⁻⁵⁸ the role of a perivascular collagenous sheath is still being learned. However,
377 we can speculate that the collagenous sheath structurally stabilizes the endothelial cells
378 within it. It is possible that both VEGF and anti-VEGF agents impact lesions with sheaths
379 principally where the sheath is absent. On transmission electron microscopy, the
380 collagenous neovascular stalk was populated by endothelial cells and pericytes that
381 either remained, self-renewed, or migrated in during cycles of varying VEGF level. MNV
382 persistence after treatment, as well as recurrence after apparent regression, may be due
383 to thick collagenous sheaths surrounding vessel walls. If so, then type 3 MNV might
384 require monitoring for disease activity by vascular characteristics in addition to fluid.

385 We showed that type 3 MNV can coexist with vascular formations that are
386 candidate precursors, early stages, and masqueraders for type 3 MNV. All three
387 DRAMA originated from the DCP within the inner ring of ETDRS and extended
388 posteriorly into the HFL. None of the DRAMA lesions involved the superficial capillary
389 plexus, and no significant intraretinal fluid was detectable on OCT over time. Like
390 pyramidal type 3 MNV (**Figure 10**), one DRAMA examined by electron microscopy had
391 non-fenestrated endothelial cells and pericytes (**Figure S14**). Unlike type 3MNV and like
392 native DCP, two DRAMA lacked a collagenous sheath. The one DRAMA with a thin
393 sheath (OD 3) also extended furthest of the three into the ONL, perhaps indicating
394 chronicity. Importantly, none of the DRAMA were accompanied by descent of the ELM,
395 the border of atrophy in neurosensory retina, although the ELM can be perforated by
396 inwardly migrating RPE as in OS 3. It is unlikely that DRAMA in our case represent
397 exudative or non-exudative perifoveal vascular anomalous complexes (ePVAC/
398 nePEVAC),^{31,35,36} which typically appear above the DCP. Microvascular anomalies in
399 eyes with neovascular and non-neovascular AMD include capillary dilations and
400 telangiectasia that are associated with locally increased VEGF expression.^{17,59-61} A
401 recent study showed that 19/94 eyes with type 3 MNV exhibited an asymptomatic

Intraretinal vascular morphologies in treated AMD

402 precursor stage on OCT.⁴³ It is possible that lack of exudation and non-progression to
403 type 3 MNV in our case might result from VEGF suppression.⁶² Longitudinal imaging is
404 required to definitively place DRAMA in the progression sequence of type 3 MNV.

405 All analyzed vessels localized within 500-1500 μm of the foveal center, aligned
406 with similar findings for solitary and multifocal type 3 MNV.^{11, 12} A role for choroidal
407 ischemia is hypothesized,^{11, 63-65} because the choroid is thinner in eyes with type 3 MNV
408 than in eyes with types 1 and 2 MNV.^{66, 67} The radial symmetry of lesions around and
409 close to the fovea further suggests an association with the distribution of photoreceptors
410 and their support cells, which vary markedly in this site. The ETDRS inner ring of type 3
411 MNV vulnerability is just peripheral to the foveal avascular zone³² on the inner slope of
412 the crest of high rod density. Rod vision in AMD eyes is poorest in this inner ring.⁶⁸⁻⁷²
413 Metabolic demand of foveal cones is very high, and choriocapillaris OCTA signal
414 decreases under the fovea throughout adulthood.^{73, 74} It is thus possible that the
415 distribution of type 3 MNV is an additional effect of microvascular changes under the
416 fovea that also contribute to high-risk drusen and reduced sustenance of nearby rods.

417 Study strengths include the availability of OCTA with eye-tracked OCT,
418 volumetric projection artifact removal, rapid tissue preservation to maintain retinal
419 attachment, registration of pre-mortem and post-mortem OCT volumes, and
420 comprehensive histologic and microscopy techniques to reveal vessels and perivascular
421 tissue elements. Limitations include the lack of longitudinal OCTA imaging^{9, 75} and lack
422 of color fundus photography to reveal discoloration patterns typical of type 3 MNV.¹⁴
423 Limitations to the laboratory study included use of stepped sections, lack of electron
424 microscopy for all lesions, and lack of immunohistochemistry to support cell type
425 identifications based on morphologic criteria. Finally, observations from one patient
426 however detailed cannot elucidate the full range of biologic variability.

Intraretinal vascular morphologies in treated AMD

427 Nevertheless, our study helped define morphologies of type 3 MNV and offered
428 candidate precursors that might guide diagnosis and disease monitoring in the future.
429 The presence and extent of a collagenous sheath distinguishes type 3MNV from normal
430 DCP vessels and may represent a stage in the evolution of DRAMA toward type 3MNV.
431 The hypotheses offered herein can be tested in the larger samples available in clinic
432 populations and clinical trial imaging datasets, ideally before onset of exudation.
433

Intraretinal vascular morphologies in treated AMD

434 **Acknowledgments**

435

436 **Contribution statement**

437 All authors were involved in drafting the article or revising it critically for important
438 intellectual content, and all authors approved the final version to be published. Dr. Curcio
439 and Dr. Berlin had full access to all the data in the clinical picture and take responsibility
440 for the integrity of the data and the accuracy of the data analysis. Study conception and
441 design: AB, DC, LC, CB, RM, DF, KBF, CC. Acquisition of data: RM, CB, JM, LC, AB,
442 DC, KBF, CC. Analysis and interpretation of data: AB, DC, LC, DF, KBF, CC. Writing of
443 manuscript: AB, DC, CB, LC, RM, DF, KBF, CC.

444

445 **Financial support**

446 This work was supported by Genentech/ Hoffman LaRoche, The Macula Foundation,
447 Inc., New York, NY; unrestricted funds to the Department of Ophthalmology and Visual
448 Sciences (UAB) from Research to Prevent Blindness, Inc., and EyeSight Foundation of
449 Alabama. AB reports grants from the Dr. Werner Jackstädt-foundation. DC was
450 supported in part by a studentship from Fundação Luso-Americana para o
451 desenvolvimento (FLAD, USA R&D@PhD – Proj 2020/0140). Purchase of the slide
452 scanner was made possible by the Carl G. and Pauline Buck Trust.

453 The sponsors had no role in the design and conduct of the study; collection,
454 management, analysis, and interpretation of the data; preparation, review, or approval of
455 the manuscript; and decision to submit the manuscript for publication.

456

Intraretinal vascular morphologies in treated AMD

457 **Financial disclosure**

458 KBF is a consultant to Genentech, Zeiss, Heidelberg Engineering, Allergan, Bayer, and
459 Novartis. CAC receives research funds from Regeneron (outside this project). DF is an
460 employee of Genentech and a stockholder of Roche.

461

462 **Meeting presentation**

463 This work was submitted as part of an abstract to the annual meeting of The Association
464 for Research in Vision & Ophthalmology (ARVO) May 2021 and May 2022.

465

466

467

468

469

Intraretinal vascular morphologies in treated AMD

470 **Figures**

471 **Figure 1. Multimodal retinal imaging of both eyes, 11 months before death.**

472 **A & D.** Fluorescein angiography (FA) in venous (**A**) and recirculation phases (**D**) shows
473 multiple instances of hyperfluorescence. Vessels were found by histology at the green,
474 yellow, and fuchsia arrowheads in the right (**A**), and left eye (**D**). At the white arrowhead
475 in the left eye, no vessel could be found in histology.

476 **B & E.** Near-infrared reflectance imaging (NIR) shows reduced reflectance in areas of
477 angiographic leakage (arrowheads), possibly due to retinal edema. Soft drusen exhibit
478 hypo- and hyperreflective mottling. Scale bar 200 μm .

479 **C & F.** Fundus autofluorescence (FAF; $\lambda_{\text{ex}} = 488 \text{ nm}$) highlights subretinal drusenoid
480 deposits especially superior to the fovea.

481 Lesion number, type, and spatial distribution are listed in [Table 2](#).

482

483 **Figure S2. Hyperfluorescence without histologic correlate, OS 2**

484 **A.** Fluorescein angiography (FA, **A1**) venous phase, 11 months before death, shows
485 multiple instances of hyperfluorescence. An optical coherence tomography (OCT) B-
486 scan (green line) displays drusen, a double-layer sign (white arrowhead), choroidal
487 hypertransmission, and hyperreflective foci (**A2**).

488 **B, C.** At 4 and 2 months before death, with 5 (**B**) and 6 (**C**) total injections, respectively,
489 the lesion is stable, without intraretinal cysts.

490

491 **Figure S3. Initial presentation of right eye, 5 years before death**

492 **A-E.** Fluorescein angiography (FA), near infrared reflectance images (NIR), and radial
493 optical coherence tomography (OCT) B-scans show exudative age-related macular
494 degeneration in the right eye at initial presentation. Based on these findings anti-VEGF
495 therapy is initiated.

496 **A.** FA recirculation phase shows marked leakage. Corresponding OCT shows
497 intraretinal and subretinal hyporefective cysts and spaces representing exudation,
498 located above drusenoid pigment epithelium detachments in the fovea and parafovea.

499 **B.** NIR and OCT show hyporefective subretinal drusenoid deposits and hyperreflective
500 soft drusen across the macula. Hyperreflective foci are present in inner and outer
501 nuclear layer.

502

Intraretinal vascular morphologies in treated AMD

503 **Figure S4. Initial presentation of left eye, 5 years before death**

504 **A-E.** Near infrared reflectance images (NIR) and radial optical coherence tomography
505 (OCT) B-scans show non-exudative age-related macular degeneration in the left eye.
506 Hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen (**B** teal and
507 fuchsia arrowheads respectively) appear across the macula.
508 **B.** On the recirculation phase of fluorescein angiography (FA), no intraretinal or
509 subretinal fluid or leakage is present, ensuring absence of active MNV exudation.
510 **F.** A shallow RPE elevation with choroidal hypertransmission (white arrowhead) and
511 hyperreflective focus was stable on longitudinal follow-up by OCT (**Figure S4**). No
512 vessel was found in histology. This lesion presumably corresponds to a calcified druse.³⁸

513

514 **Figure 5. Multimodal imaging, clinical course, and histology of pyramidal type 3** 515 **MNV, OS 4.**

516 **A.** Venous phase fluorescein angiography (FA, **A1**) shows mild leakage at site of type 3
517 MNV 11 months before death. Green lines on FA represent optical coherence
518 tomography (OCT) B-scans. Horizontal OCT B-scan (**A2**) displays a hyperreflective
519 lesion, hyperreflective foci (HRF), and small intraretinal cysts.
520 **B.** Blue lines on near-infrared reflectance (NIR, **B1**), represents histology section in **D**.
521 Radial OCT B-scan (**B2**) displays enlarged intraretinal cysts, after 5 total injections and 8
522 weeks following the prior injection. There is also subsidence of the outer plexiform layer
523 (OPL) and external limiting membrane (ELM).
524 **C.** On radial OCT B-scan (**C2**), intraretinal fluid is reduced after 6 injections and 6 weeks
525 following the prior injection. Numerous HRF are present in the inner nuclear layer (INL;
526 **C2**; scale bar 200 μm).
527 **D.** On histology, type 3 MNV is a pyramidal complex bounded by retinal pigment
528 epithelium cells. It extends from the INL/ OPL border to basal laminar deposit draping a
529 calcified druse. Structural damage to Henle's fiber layer at the right of the panel (green
530 asterisk) may indicate an area of prior intraretinal fluid. Magnified histology is shown in
531 **Figure 6**. Scale bar 100 μm .
532 Blue line, histology section. Time in months, time before death.

533

Intraretinal vascular morphologies in treated AMD

534 **Figure 6. Pyramidal vascular complex in type 3 MNV, OS 4.**

535 **A, B.** A pyramidal complex includes neovessels ensheathed by thick layers of
536 collagenous material and flanked by retinal pigment epithelium cells. The complex
537 extends from the inner nuclear layer (INL) through the outer plexiform layer, Henle fiber
538 layer, outer nuclear layer (OPL, HFL, ONL, respectively) and terminates at the basal
539 laminar deposits draping a calcified druse. Bruch's membrane appears intact with no
540 evidence of a choroidal contribution to the neovessel complex. The external limiting
541 membrane (ELM) descends at both sides of type 3 MNV base. There is some fluid at the
542 OPL-HFL border (yellow asterisk in **B**). Areas within dotted green boxes are shown in
543 **Figure 10.**

544

545 **Figure 7. Transmission electron microscopy of pyramidal type 3 MNV, OS 4.**

546 See Figure 8 for light microscopy of OS4. **A.** Neovessel with erythrocyte in the lumen
547 (blue asterisk) is ensheathed by endothelium, pericyte, and collagenous material (purple,
548 white, and black asterisks, respectively). Surrounding retinal pigment epithelium (RPE)
549 cells merge into multi-nucleated cells (red asterisk) or disperse into the Henle fiber layer
550 (HFL, green asterisk). Phagolysosomes are not visible in the RPE cells.

551 **B-D.** Endothelial cells in the neovessel and comparison vessels are displayed. The
552 lumen is located at the bottom of all panels.

553 **B.** No fenestrations are detected in the neovessel (orange arrowheads).

554 **C.** Fenestrations are visible in the choriocapillaris (orange arrowheads).

555 **D.** No fenestrations are detected in the deep capillary plexus (orange arrowheads).

556 **E.** Atop the calcified druse (fuchsia asterisk), RPE lipofuscin is more electron-dense at
557 the druse base than at the druse top (left vs right in the panel). These changes are
558 consistent with transdifferentiation.

559

560 **Figure 8. Multimodal imaging, clinical course, and histology of tangled type 3** 561 **MNV, OD 1.**

562

563 **A.** Green and red lines on near-infrared reflectance (NIR, **A1**) represent optical
564 coherence tomography (OCT) B-scans corresponding to en face OCT angiography
565 (OCTA, **A2**) and OCT B-scan with flow signal overlay (**A3**). After 29 total injections and 8
566 weeks following the prior injection (**A2&A3**), flow signal persists within the tangled
567 hyperreflective type 3 MNV lesion (green arrowhead). The RPE/Bruch's membrane

Intraretinal vascular morphologies in treated AMD

568 complex is split by hyporeflective material and appears as a “double layer” sign without
569 flow signal (**A3**). Red lines in **A2** indicate the segmentation boundaries [outer plexiform
570 layer (OPL)-retinal pigment epithelium (RPE)] used to create the en face OCTA (**A2**).
571 **B**. Fluorescein angiography (FA, **B1**) shows late venous phase hyperfluorescence, after
572 32 total injections and 8 weeks following the last injection. OCT B-scan (**B2**) shows
573 intraretinal fluid in the inner nuclear and Henle fiber layers surrounding the type 3 MNV
574 lesion (green arrowhead).
575 **C**. NIR (**C1**) and radially oriented OCT B-scan (**C2**) shows intraretinal fluid adjacent to
576 the tangled type 3 MNV lesion (green arrowhead), after 36 total injections and 8 weeks
577 following the prior injection. Blue line in **C1** represents histology section in panel **D**.
578 **D**. Panoramic histology shows a horizontally oriented tangled type 3 MNV lesion (green
579 arrowhead), partly bounded by RPE cells (scale bar 200 μm). The complex extends from
580 the inner nuclear layer border to a calcified druse, which correlates to the double layer
581 sign in B1. The druse is draped by basal laminar deposit and lacks RPE at its apex.
582 Time in months, time before death; BCVA, best corrected visual acuity.

583

584 **Figure 9. Volume rendering of structural optical coherence tomography (OCT, gray) and OCT angiography (OCTA, yellow) of tangled type 3 MNV, OD 1.**

586 **A**. Neovascular blood flow within a hyperreflective structure (white arrowheads) is
587 observed at the level of the outer nuclear layer (ONL).
588 **B**. Three-dimensional analysis of neovascular blood flow depict an anastomosis above
589 the retinal pigment epithelium (RPE)/ Bruch’s membrane (BrM; green section) and a
590 tangled structure connecting to the superficial artery (red arrow) and vein (blue arrow).
591 **C**. Volume rendering of OCTA with orthogonal structural sections evidence a tangled
592 neovascular lesion.

593

594 **Figure S10. Tangled vascular complex in type 3 MNV, OD 1.**

595 **A-C**. Tangled vascular complex (fuchsia arrowheads indicate lumen) spans 249 μm
596 horizontally towards the superior perifovea (**A**, 759 μm from fovea; **B**, 719 μm from fovea;
597 **C**, 552 μm from fovea). The complex is partly ensheathed by collagenous material and is
598 flanked by retinal pigment epithelium (RPE) cells. Two cells rest entirely within the outer
599 plexiform layer (OPL)/ inner nuclear layer (INL; light blue arrowhead in **A**). The INL/OPL
600 subsides, and the vascular complex extends from the INL/OPL border through the Henle
601 fiber layer (HFL)/ outer nuclear layer (ONL). The complex adheres to basal laminar

Intraretinal vascular morphologies in treated AMD

602 deposits (BLamD) draping a calcified druse (d). Bruch's membrane (BrM) appears intact
603 without evidence of a choroidal contribution. The external limiting membrane (ELM)
604 descends at both edges of the calcified druse (yellow arrowheads in **B**). Vessel walls do
605 not exhibit obvious arterial or venous features. Vessel diameter within the INL was larger
606 than 15 μm , suggesting drainage venules.

607

608 **Figure 11. Deep retinal age-related microvascular anomaly (DRAMA), OS1.**

609 **A.** Near infrared reflectance (NIR) shows drusen and subretinal drusenoid deposits 11
610 months before death. Blue line, plane of histology section.

611 **B.** Fluorescein angiography (FA) recirculation phase shows minimal leakage at the site
612 of DRAMA.

613 **C.** On histology, a vessel extends downwards (yellow arrowheads) from the inner
614 nuclear layer (INL) into the outer plexiform layer (OPL) above a druse.

615

616 **Figure 12. Multimodal imaging and histology of deep retinal age-related 617 microvascular anomaly (DRAMA) with intraretinal RPE complex, OS 3.**

618

619 **A.** Fluorescein angiography (FA) venous phase shows faint staining, 11 months before
620 death (**A1**). Optical coherence tomography (OCT, **A2**) shows a stack of intraretinal
621 hyperreflective foci (HRF, fuchsia arrowhead). No intraretinal cysts are visible.

622 **B.** After 6 total injections and 6 weeks following the prior injection, the stacked lesion
623 (fuchsia arrowhead) is stable, without cysts. A plume of HRF extend nasally 2 months
624 before death. Green lines, OCT B-scans; blue line, histology section.

625 **C.** On histology, a retinal pigment epithelium tower (fuchsia arrowhead) rises upward
626 from a soft druse. Cells surround a vessel and extend into the outer plexiform layer.

627 Magnified histology is shown in [Figure 13](#).

628

629 **Figure 13. RPE complex associated with deep retinal age-related microvascular 630 anomaly (DRAMA), OS 3.**

631 **A.** A "hand" shaped complex consisting of retinal pigment epithelium (RPE) cells
632 surrounds vessel extending downward from the deep capillary plexus. Electron
633 microscopy of the area in the dotted fuchsia box is shown in [Figure S14](#).

634 **B.** The RPE complex extends upward to the inner nuclear layer (INL). On either side of
635 this complex, there is no subsidence of outer plexiform layer (OPL) or external limiting

Intraretinal vascular morphologies in treated AMD

636 membrane (ELM), and the outer nuclear layer (ONL) is thinned. The complex emanates
637 from a continuous RPE layer over basal laminar deposit (BLamD) and a soft druse. The
638 druse is artifactually detached from Bruch's membrane (BrM).

639 **C-E.** Endothelial cell (EC) ultrastructure in DRAMA and comparison vessels are shown.

640 Vascular lumen is at the bottom of all panels.

641 **C.** No fenestrations are visible in the DRAMA (red blood cell, RBC).

642 **D.** No fenestrations are visible in the deep capillary plexus (pericyte, P).

643 **E.** Fenestrations are visible in the choriocapillaris endothelium (orange arrowheads;
644 white blood cell, WBC).

645

646 **Figure S14. Transmission electron microscopy of DRAMA with RPE complex, OS**

647 **3.**

648 The Vessel is ensheathed by an endothelial (E) cell and a pericyte (P), with little
649 collagen. The Lumen contains a leukocyte (LC) and a red blood cell (RBC). The
650 surrounding tower of retinal pigment epithelium (RPE) is multicellular (white asterisk),
651 and multinucleated (fuchsia asterisks). RPE organelle packing density and electron-
652 density is similar to in-layer RPE cells (not shown).

653

654 **Figure 15. Multimodal imaging of deep retinal age-related microvascular**
655 **anomalies (DRAMAs), OD 3.**

656 **A.** Fluorescein angiography (FA) venous phase shows mild hyperfluorescence 11
657 months before death. **B.** Green and blue lines on near-infrared reflectance (NIR),
658 represent optical coherence tomography (OCT) B-scan (C) and histology section (D). **C.**

659 Horizontally oriented OCT B-scan with OCT angiography (OCTA) flow overlay shows
660 cyst-like spaces in the Henle fiber layer adjacent to a pair of hyperreflective DRAMAs
661 (fuchsia arrowheads). The retinal pigment epithelium/Bruch's membrane complex to the
662 left is split by hyporefective material. **D.** OCTA shows a pair of intraretinal flow signals
663 (fuchsia arrowheads). **E.** Histology shows a pair of vessels extending from the inner
664 nuclear layer border to the outer nuclear layer. Magnified histology is shown in **Figure**

665 **16.**

666

Intraretinal vascular morphologies in treated AMD

667 **Figure 16. Vascular complex of deep retinal age-related microvascular anomaly**
668 **(DRAMA), OD 3.**

669
670 **A, B.** A penetrating pair of vessels, (DRAMAs, fuchsia arrowheads) ensheathed by
671 collagenous material dives from the inner nuclear layer (INL) into the Henle fiber layer
672 (HFL)/outer nuclear layer (ONL). Next to the vessels is a degenerative cyst in the Henle
673 fiber layer (HFL). There is no subsidence of external limiting membrane (ELM). The ONL
674 is thinned.

675 **C.** Retinal pigment epithelium (RPE) from the edge of a druse (d) migrates towards the
676 lower edge of the vessel complex, right side.

677 **Supplementary Video**

678

679 **Video S1.**

680

681 **Volume rendering of structural OCT (gray) and OCTA (yellow) of tangled type 3 MNV, OD 1 (Fig. 5).**

682

683

684 demonstrates neovascular blood flow within an hyperreflective structure at the outer nuclear layer and above Bruch's membrane

685 (BrM). The superficial arteries (red) and veins (blue) in the vicinity of the lesion are outlined after fluorescein angiography analysis.

686 Three-dimensional analysis of neovascular blood flow depicts an anastomosis right above BrM (green section) Spinning around the

687 neovascular blood-flow highlights separate inflow and outflow.

688

689

690

691

Intraretinal vascular morphologies in treated AMD

References

1. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? , *Retina*. 2010;30(9):1333-49.
2. Su D, Lin S, Phasukkijwatana N, et al. An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. *Retina* 2016;36:S40-S9.
3. Berlin A, Cabral D, Chen L, et al. Correlation of Optical Coherence Tomography Angiography of Type 3 Macular Neovascularization With Corresponding Histology. *JAMA Ophthalmol*. 2022;140(6):628-633.
4. Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. *Ophthalmology* 2020;127(5):616-36.
5. Yannuzzi LA, Negrão S, Tomohiro I, et al. Retinal angiomatous proliferation in age-related macular degeneration. *Retina* 2012;32:416-34.
6. Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. *American Journal of Ophthalmology* 2014;158(4):769-79. e2.
7. Kim JH, Kim JW, Kim CG, Lee DW. Influence of fellow-eye examination interval on visual acuity at fellow-eye neovascularization in unilateral type 3 neovascularization. *Retina* 2020;40(7):1255-61.
8. Kwak JH, Park WK, Kim RY, et al. Unaffected fellow eye neovascularization in patients with type 3 neovascularization: Incidence and risk factors. *PLoS One* 2021;16(7):e0254186.
9. Sacconi R, Forte P, Capuano V, et al. OCT-A characterization of evolving lesions in fellow eyes of exudative type 3 MNV patients. *Retina* 2022;10.1097.
10. Freund KB, Ho I-V, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. *Retina* 2008;28(2):201-11.
11. Najeeb BH, Deak G, Schmidt-Erfurth U, Gerendas BS. The RAP study, report two: the regional distribution of macular neovascularization type 3, a novel insight into its etiology. *Retina* 2020;40(12):2255-62.
12. Haj Najeeb B, Deak GG, Sacu S, et al. The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3. *Graefes Archive for Clinical and Experimental Ophthalmology* 2022;260(1):141-7.
13. Haj Najeeb B, Deak GG, Schmidt-Erfurth U, Gerendas BS. The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3. *Acta Ophthalmologica* 2021.
14. Borrelli E, Sacconi R, Klose G, et al. Rotational three-dimensional OCTA: a notable new imaging tool to characterize type 3 macular neovascularization. *Scientific Reports* 2019;9(1):1-8.
15. Shimada H, Kawamura A, Mori R, Yuzawa M. Clinicopathological findings of retinal angiomatous proliferation. *Graefes Archive for Clinical and Experimental Ophthalmology* 2007;245(2):295-300.
16. Li M, Dolz-Marco R, Messinger JD, et al. Clinicopathologic Correlation of Anti-Vascular Endothelial Growth Factor-Treated Type 3 Neovascularization in Age-Related Macular Degeneration. *Ophthalmology* 2018;125(2):276-87.
17. Sacconi R, Freund KB, Yannuzzi LA, et al. The expanded spectrum of perifoveal exudative vascular anomalous complex. *American Journal of Ophthalmology* 2017;184:137-46.
18. Gilani F, Gal-Or O, Freund KB. Spontaneous rupture and involution of a “macro-microaneurysm” in diabetic retinopathy. *Retina* 2017;37(6):e73-e4.

Intraretinal vascular morphologies in treated AMD

19. Spaide RF, Barquet LA. Retinal capillary macroaneurysms. *Retina* 2019;39(10):1889-95.
20. Sacconi R, Cohen SY, Borrelli E, et al. Correspondence. *Retina* 2019;39(11):e48-e9.
21. Spaide RF. Correspondence Reply. *Retina* 2019;39(11):E49-E50.
22. Sacconi R, Borrelli E, Sadda S, et al. Nonexudative perifoveal vascular anomalous complex: the subclinical stage of perifoveal exudative vascular anomalous complex? *American Journal of Ophthalmology* 2020;218:59-67.
23. Querques G, Kuhn D, Massamba N, et al. Perifoveal exudative vascular anomalous complex. *Journal Français d'Ophthalmologie* 2011;34(8):559. e1-. e4.
24. Cabral D, Ramtohul P, Fradinho A, Freund KB. Volume Rendering of Deep Retinal Age-Related Microvascular Anomalies. *Ophthalmol Retina* 2022.
25. Chen L, Messinger JD, Sloan KR, et al. Nonexudative macular neovascularization supporting outer retina in age-related macular degeneration: a clinicopathologic correlation. *Ophthalmology* 2020;127(7):931-47.
26. Querques G, Querques L, Forte R, et al. Precursors of type 3 neovascularization: a multimodal imaging analysis. *Retina* 2013;33(6):1241-8.
27. Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;310(20):2191-4.
28. Edemekong P, Annamaraju P, Haydel M. Health Insurance Portability and Accountability Act.[Updated 2021 Feb 4]. StatPearls Treasure Island (FL): StatPearls Publishing 2021.
29. Rocholz R, Teussink M, Dolz-Marco R, et al. SPECTRALIS optical coherence tomography angiography (OCTA): principles and clinical applications. *Heidellb Eng Acad* 2018 (September):1-10.
30. Cabral D, Fradinho AC, Pereira T, et al. Macular Vascular Imaging and Connectivity Analysis Using High-Resolution Optical Coherence Tomography. *Translational Vision Science & Technology* 2022;11(6):2-.
31. Xu X, Yannuzzi NA, Fernández-Avellaneda P, et al. Differentiating veins from arteries on optical coherence tomography angiography by identifying deep capillary plexus vortices. *American Journal of Ophthalmology* 2019;207:363-72.
32. Kim JH, Chang YS, Kim JW, et al. Characteristics of type 3 neovascularization lesions: focus on the incidence of multifocal lesions and the distribution of lesion location. *Retina* 2020;40(6):1124-31.
33. Group ETDRSR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification: ETDRS report number 10. *Ophthalmology* 1991;98(5):786-806.
34. Pongsachareonnont P, Somkijrungraj T, Assavapongpaiboon B, et al. Foveal and parafoveal choroidal thickness pattern measuring by swept source optical coherence tomography. *Eye* 2019;33(9):1443-51.
35. Balaratnasingam C, An D, Sakurada Y, et al. Comparisons between histology and optical coherence tomography angiography of the periarterial capillary-free zone. *American Journal of Ophthalmology* 2018;189:55-64.
36. Litts KM, Messinger JD, Dellatorre K, et al. Clinicopathological correlation of outer retinal tubulation in age-related macular degeneration. *JAMA Ophthalmology* 2015;133(5):609-12.
37. Balaratnasingam C, An D, Freund KB, et al. Correlation between histologic and OCT angiography analysis of macular circulation. *Ophthalmology* 2019;126(11):1588-9.
38. Berlin A MJ, Ferrara D, Freund KB, Curcio CA. OCT features relevant to neovascular AMD management and non-neovascular AMD progression: clinicopathologic correlation. *Retinal Cases and Brief Reports* 2022 ; 9900:10.1097.
39. Berlin A, Chen L, Messinger J, et al. Double-layer sign in neovascular age-related macular degeneration—do we treat? *Acta Ophthalmologica* 2022;100(3):348-9.
40. Snodderly DM, Weinhaus RS, Choi J. Neural-vascular relationships in central retina of macaque monkeys (*Macaca fascicularis*). *Journal of Neuroscience* 1992;12(4):1169-93.

Intraretinal vascular morphologies in treated AMD

41. Balaratnasingam C, Messinger JD, Sloan KR, et al. Histologic and optical coherence tomographic correlates in drusenoid pigment epithelium detachment in age-related macular degeneration. *Ophthalmology* 2017;124(5):644-56.
42. Cao D, Leong B, Messinger JD, et al. Hyperreflective foci, optical coherence tomography progression indicators in age-related macular degeneration, include transdifferentiated retinal pigment epithelium. *Investigative Ophthalmology & Visual Science* 2021;62(10):34-.
43. Najeeb BH, Deak GG, Mylonas G, et al. The RAP study, report 5: rediscovering macular neovascularization Type 3: multimodal imaging of fellow eyes over 24 months. *Retina* 2022;42(3):485.
44. Najeeb BH, Deak GG, Schmidt-Erfurth UM, Gerendas BS. RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3. *British Journal of Ophthalmology* 2021;105(1):113-7.
45. Querques G, Souied EH, Freund KB. How has high-resolution multimodal imaging refined our understanding of the vasogenic process in type 3 neovascularization? *Retina* 2015; 35(4):603-13.
46. Borrelli E, Souied EH, Freund KB, et al. Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration. *Retina* 2018; 38(10):1968-76.
47. Koizumi H, Iida T, Saito M, et al. Choroidal circulatory disturbances associated with retinal angiomatic proliferation on indocyanine green angiography. *Graefes Archive for Clinical and Experimental Ophthalmology* 2008;246(4):515-20.
48. Spaide RF. Fundus autofluorescence and age-related macular degeneration. *Ophthalmology* 2003;110(2):392-9.
49. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatic proliferation or type 3 neovascularization. *Retina*. 2008; 28(3):375-84
50. Cho HJ, Lim SH, Kim J, et al. Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography. *Graefes Archive for Clinical and Experimental Ophthalmology* 2021:1-9.
51. Kim JH, Chang YS, Kim JW, et al. Difference in treatment outcomes according to optical coherence tomography–based stages in type 3 neovascularization (retinal angiomatic proliferation). *Retina* 2018; 38(12):2356-62.
52. Sacconi R, Battista M, Borrelli E, et al. OCT-A characterisation of recurrent type 3 macular neovascularisation. *British Journal of Ophthalmology* 2021;105(2):222-6.
53. Huang D, Jia Y, Rispoli M, et al. OCT angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment. *Retina* 2015;35(11):2260.
54. Skalet AH, Miller AK, Klein ML, et al. Clinicopathologic correlation of retinal angiomatic proliferation treated with ranibizumab. *Retina* 2017;37(8):1620.
55. Han JW, Cho HJ, Kang DH, et al. Changes in optical coherence tomography angiography and disease activity in type 3 neovascularization after anti-vascular endothelial growth factor treatment. *Retina* 2020;40(7):1245-54.
56. Timpl R, Brown JC. Supramolecular assembly of basement membranes. *Bioessays* 1996;18(2):123-32.
57. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. *Annual Review of Cell and Developmental Biology* 2004;20:255.
58. Erickson AC, Couchman JR. Still more complexity in mammalian basement membranes. *Journal of Histochemistry & Cytochemistry* 2000;48(10):1291-306.
59. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. *Ophthalmology* 1996;103(11):1820-8.
60. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. *American Journal of Ophthalmology* 2002;133(3):373-85.

Intraretinal vascular morphologies in treated AMD

61. Jackson TL, Danis RP, Goldbaum M, et al. Retinal vascular abnormalities in neovascular age-related macular degeneration. *Retina* 2014;34(3):568-75.
62. Spaide RF. New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings. *Retina* 2019;39(8):1451-64.
63. Hayreh SS. Segmental nature of the choroidal vasculature. *British Journal of Ophthalmology* 1975;59(11):631-48.
64. Hayreh SS. In vivo choroidal circulation and its watershed zones. *Eye* 1990;4(2):273-89.
65. Hayreh SS. Posterior ciliary artery circulation in health and disease the Weisenfeld lecture. *Investigative Ophthalmology & Visual Science* 2004;45(3):749-57.
66. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness in retinal angiomatous proliferation. *Retina* 2014;34(7):1316-22.
67. Kim JH, Kim JR, Kang SW, et al. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. *American journal of ophthalmology* 2013;155(4):743-9. e2.
68. Tan R, Guymer RH, Luu CD. Subretinal drusenoid deposits and the loss of rod function in intermediate age-related macular degeneration. *Investigative Ophthalmology & Visual Science* 2018;59(10):4154-61.
69. Tan RS, Guymer RH, Aung K-Z, et al. Longitudinal assessment of rod function in intermediate age-related macular degeneration with and without reticular pseudodrusen. *Investigative Ophthalmology & Visual Science* 2019;60(5):1511-8.
70. Chen KG, Alvarez JA, Yazdanie M, et al. Longitudinal study of dark adaptation as a functional outcome measure for age-related macular degeneration. *Ophthalmology* 2019;126(6):856-65.
71. Zhang Y, Sadda SR, Sarraf D, et al. Spatial Dissociation of Subretinal Drusenoid Deposits and Impaired Scotopic and Mesopic Sensitivity in AMD. *Investigative Ophthalmology & Visual Science* 2022;63(2):32-.
72. Nigalye AK, Hess K, Pundlik SJ, et al. Dark Adaptation and Its Role in Age-Related Macular Degeneration. *Journal of Clinical Medicine* 2022;11(5):1358.
73. Zheng F, Zhang Q, Shi Y, et al. Age-dependent changes in the macular choriocapillaris of normal eyes imaged with swept-source optical coherence tomography angiography. *American Journal of Ophthalmology* 2019;200:110-22.
74. Ingram NT, Fain GL, Sampath AP. Elevated energy requirement of cone photoreceptors. *Proceedings of the National Academy of Sciences* 2020;117(32):19599-603.
75. Borrelli E, Mastropasqua L, Souied E, et al. Longitudinal assessment of type 3 macular neovascularization using three-dimensional volume-rendering optical coherence tomography angiography. *Canadian Journal of Ophthalmology* 2021.




Figure S2. Hyperfluorescence without histologic correlate, OS 2

A. Fluorescein angiography (FA, **A1**) venous phase, 11 months before death, shows multiple instances of hyperfluorescence. An optical coherence tomography (OCT) B-scan (green line) displays drusen, a double-layer sign (white arrowhead), choroidal hypertransmission, and hyperreflective foci (**A2**).

B, C. At 4 and 2 months before death, with 5 (**B**) and 6 (**C**) total injections, respectively, the lesion is stable, without intraretinal cysts.




Figure S3. Initial presentation of right eye, 5 years before death

A-E. Fluorescein angiography (FA), near infrared reflectance images (NIR), and radial optical coherence tomography (OCT) B-scans show exudative age-related macular degeneration in the right eye at initial presentation. Based on these findings anti-VEGF therapy is initiated.

A. FA recirculation phase shows marked leakage. Corresponding OCT shows intraretinal and subretinal hyporeflective cysts and spaces representing exudation, located above drusenoid pigment epithelium detachments in the fovea and parafovea.

B. NIR and OCT show hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen across the macula. Hyperreflective foci are present in inner and outer nuclear layer.




Figure S4. Initial presentation of left eye, 5 years before death

A-E. Near infrared reflectance images (NIR) and radial optical coherence tomography (OCT) B-scans show non-exudative age-related macular degeneration in the left eye. Hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen (**B** teal and fuchsia arrowheads respectively) appear across the macula.

B. On the recirculation phase of fluorescein angiography (FA), no intraretinal or subretinal fluid or leakage is present, ensuring absence of active MNV exudation.

F. A shallow RPE elevation with choroidal hypertransmission (white arrowhead) and hyperreflective focus was stable on longitudinal follow-up by OCT (**Figure S4**). No vessel was found in histology. This lesion presumably corresponds to a calcified druse.³⁸






Figure S10. Tangled vascular complex in type 3 MNV, OD 1.

A-C. Tangled vascular complex (fuchsia arrowheads indicate lumen) spans 249 μm horizontally towards the superior perifovea (**A**, 759 μm from fovea; **B**, 719 μm from fovea; **C**, 552 μm from fovea). The complex is partly ensheathed by collagenous material and is flanked by retinal pigment epithelium (RPE) cells. Two cells rest entirely within the outer plexiform layer (OPL)/ inner nuclear layer (INL; light blue arrowhead in **A**). The INL/OPL subsides, and the vascular complex extends from the INL/OPL border through the Henle fiber layer (HFL)/ outer nuclear layer (ONL). The complex adheres to basal laminar deposits (BLamD) draping a calcified druse (d). Bruch's membrane (BrM) appears intact without evidence of a choroidal contribution. The external limiting membrane (ELM) descends at both edges of the calcified druse (yellow arrowheads in **B**). Vessel walls do not exhibit obvious arterial or venous features. Vessel diameter within the INL was larger than 15 μm , suggesting drainage venules.




Figure S14. Transmission electron microscopy of DRAMA with RPE complex, OS 3.

The Vessel is ensheathed by an endothelial (E) cell and a pericyte (P), with little collagen. The Lumen contains a leukocyte (LC) and a red blood cell (RBC). The surrounding tower of retinal pigment epithelium (RPE) is multicellular (white asterisk), and multinucleated (fuchsia asterisks). RPE organelle packing density and electron-density is similar to in-layer RPE cells (not shown).